AVHHL / AVITA Medical, Inc. - Depositary Receipt (Common Stock) - Pemfailan SEC, Laporan Tahunan, Penyata Proksi

FORM 8-K Item 3.02. Unregistered Sales of Equity Securities.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2025 AVITA Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39059 85-1021707 (State or Other Jurisdiction of Incorporation) (Commission Fil

FORM 8-K Item 8.01. Other Events.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2025 AVITA Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39059 85-1021707 (State or Other Jurisdiction of Incorporation) (Commission Fil

AVITA Medical Successfully Completes Australian Equity Raise

Exhibit 99.1 AVITA Medical Successfully Completes Australian Equity Raise • Private placement of approximately 17.2 million new CHESS Depositary Interests (“New CDIs”) quoted on the Australian Securities Exchange (ASX) • Issue price of A$1.32 per New CDI, raising approximately US$15 million (~A$23 million), with participation from new and existing Australian shareholders VALENCIA, Calif., August 1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39059 AVITA MEDICAL, INC. (

EXPLANATORY NOTE PART I PART II + Filed herewith SIGNATURES AVITA MEDICAL, INC.

As filed with the Securities and Exchange Commission on August 8, 2025 Registration No.

AVITA Medical, Inc. 400,000 Shares of Common Stock

Filed Pursuant to Rule 424(b)(5) Registration No. 333-271276 PROSPECTUS SUPPLEMENT (to the Prospectus dated April 25, 2023) AVITA Medical, Inc. 400,000 Shares of Common Stock Pursuant to this prospectus supplement and the accompanying prospectus, we are offering an aggregate of 400,000 shares of common stock (“Shares”) directly to two investors in consideration of entering into the Fifth Amendment

Third Amendment to Lease Agreement between the registrant and Hartco Ventura Inc. dated April 1, 2025 *

Exhibit 10.1 THIRD AMENDMENT TO LEASE (Units I,J,K,L,M,N,H) THIS THIRD AMENDMENT TO LEASE made and entered into this 11th day of March, 2025 by and between Hartco-Ventura, Inc. as current Landlord, hereinafter referred to as "Lessor", and Avita Medical Americas, LLC, A Delaware Limited Liability Company hereinafter referred to as "Lessee". WITNESSETH WHEREAS, Lessor leased certain premises in the

Filing Fee Table*

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) AVITA Medical, Inc.

Waiver to the Credit Agreement between the Lender and the Company, dated June 30, 2025 *

Exhibit 10.3 WAIVER This WAIVER (this “Waiver”) is made and entered into as of June 30, 2025 (the “Effective Date”) by and among AVITA MEDICAL, INC., a Delaware corporation (the “Borrower”), ORCO IV LLC and ORBIMED ROYALTY & CREDIT OPPORTUNITIES IV OFFSHORE, LP, as Lenders, and ORCO IV LLC, as administrative agent for the Lenders (together with its Affiliates, successors, transferees and assignees

AVITA Medical Reports Second Quarter 2025 Financial Results, Updates Full-Year Guidance, and Highlights Continued Clinical Innovation

Exhibit 99.1 AVITA Medical Reports Second Quarter 2025 Financial Results, Updates Full-Year Guidance, and Highlights Continued Clinical Innovation VALENCIA, Calif., August 7, 2025 (GLOBE NEWSWIRE) — AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today reported financial results for the second quarter ended June 30,

Waiver and Fifth Amendment to the Credit Agreement between the Lender and the Company, dated August 7, 2025

Exhibit 10.1 WAIVER AND FIFTH AMENDMENT TO CREDIT AGREEMENT This WAIVER AND FIFTH AMENDMENT TO CREDIT AGREEMENT (this “Amendment”) is made and entered into as of August 7, 2025 by and among AVITA MEDICAL, INC., a Delaware corporation (the “Borrower”), ORCO IV LLC and ORBIMED ROYALTY & CREDIT OPPORTUNITIES IV OFFSHORE, LP, as Lenders, and ORCO IV LLC, as administrative agent for the Lenders (togeth

FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 07, 2025 AVITA Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39059 85-1021707 (State or Other Jurisdiction of Incorporation) (Commission Fil

AVITA Medical Announces Appointment of Michael Tarnoff, MD, FACS, to its Board of Directors and Transition of Board Chair Role to Cary Vance

Exhibit 99.1 AVITA Medical Announces Appointment of Michael Tarnoff, MD, FACS, to its Board of Directors and Transition of Board Chair Role to Cary Vance • Dr. Tarnoff brings extensive executive and medical leadership experience from various organizations, including Tufts Medical Center and Medtronic. • The Board thanks Lou Panaccio, its long-standing Board Chair, for his service as he steps down

Offer Letter, dated May 27, 2025, between AVITA Medical, Inc. and Dr. Michael Tarnoff

Exhibit 10.1 May 27, 2025 Michael Tarnoff, M.D. 240 Devonshire Street Boston, MA 02110 Re: Appointment to Board of Directors Matter No. 20250846186 Dear Dr. Tarnoff, I am pleased to confirm our offer regarding your appointment as a non-executive member (a “Non-Executive Director”) of the Board of Directors (the “Board”) of AVITA Medical, Inc., a Delaware corporation (the "Company"), which will com

FORM 8-K Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 06, 2025 AVITA Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39059 85-1021707 (State or Other Jurisdiction of Incorporation) (Commission Fil

FORM 8-K Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Item 5.07 Submission of Matters to a Vote of Security Holders.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 04, 2025 AVITA Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39059 85-1021707 (State or Other Jurisdiction of Incorporation) (Commission File

FORM 8-K Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. Amended and Restated Bylaws of AVITA Medical, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2025 AVITA Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39059 85-1021707 (State or Other Jurisdiction of Incorporation) (Commission File N

Amended and Restated Bylaws (filed as Exhibit 3.1 to the Registrant’s Form 8-K filed with the SEC on May 15, 2025 and incorporated herein by reference)

Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF AVITA MEDICAL INC. ARTICLE I Meeting of Stockholders Section 1.1. Annual Meetings. If required by applicable law, an annual meeting of stockholders shall be held for the election of directors at such date, time and place, if any, either within or without the State of Delaware, as may be designated by resolution of the board of directors (the "Board of Dir

Waiver to the Credit Agreement between the Lender and the Company, dated March 31, 2025

Exhibit 10.4 WAIVER This WAIVER (this “Waiver”) is made and entered into as of March 31, 2025 (the “Effective Date”) by and among AVITA MEDICAL, INC., a Delaware corporation (the “Borrower”), ORCO IV LLC and ORBIMED ROYALTY & CREDIT OPPORTUNITIES IV OFFSHORE, LP, as Lenders, and ORCO IV LLC, as administrative agent for the Lenders (together with its Affiliates, successors, transferees and assignee

AVITA Medical Reports First Quarter 2025 Financial Results

Exhibit 99.1 AVITA Medical Reports First Quarter 2025 Financial Results VALENCIA, Calif., May 8, 2025 (GLOBE NEWSWIRE) — AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Highlights and Recent Developments • Commer

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 08, 2025 AVITA Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39059 85-1021707 (State or Other Jurisdiction of Incorporation) (Commission File N

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39059 AVITA MEDICAL, INC.

Annexure A 2020 OMNIBUS INCENTIVE PLAN AMENDED AND RESTATED (March 4, 2025)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to Section 240.

Annexure A 2020 OMNIBUS INCENTIVE PLAN AMENDED AND RESTATED (March 4, 2025)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to Section 240.

Amendment Two to the Exclusive Distribution Agreement between AVITA Medical and Stedical Scientific, Inc. dated March 17, 2025

Exhibit 10.2 Amendment Two to the Exclusive Distribution Agreement This Amendment Two (this “Amendment Two”), is effective as of March 17, 2025 (the “Effective Date”), and amends the Exclusive Distribution Agreement with an Effective Date of January 10, 2024, previously amended on April 30, 2024 (the “Agreement”), by and between AVITA Medical Americas, LLC (“Distributor”) and Stedical Scientific,

Contract Manufacturing Agreement between AVITA Medical and Stedical Scientific, Inc. dated March 17, 2025

Exhibit 10.1 Contract Manufacturing Agreement This Contract Manufacturing Agreement, (the "Agreement"), is effective as of March 17, 2025 (the “Effective Date”) and is entered into by and between AVITA Medical Americas, LLC having its principle place of business at 28159 Avenue Stanford, Suite 220 Valencia, CA ("Seller"), and Stedical Scientific, Inc. having its principle place of business at 2888

AVITA Medical Announces Exclusive Manufacturing and Distribution Agreements with Stedical Scientific

Exhibit 99.1 AVITA Medical Announces Exclusive Manufacturing and Distribution Agreements with Stedical Scientific VALENCIA, Calif., March 17, 2025 (GLOBE NEWSWIRE) — AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today announced it has entered into a new Contract Manufacturing Agreement for PermeaDerm® Biosynthetic

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2025 AVITA Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39059 85-1021707 (State or Other Jurisdiction of Incorporation) (Commission File

AVITA Medical, Inc. Warrants to Purchase an Aggregate of 145,180 Shares of Common Stock

Filed Pursuant to Rule 424(b)(5) Registration No. 333-271276 PROSPECTUS SUPPLEMENT (to the Prospectus dated April 25, 2023) AVITA Medical, Inc. Warrants to Purchase an Aggregate of 145,180 Shares of Common Stock Pursuant to this prospectus supplement and the accompanying prospectus, we are offering warrants to purchase an aggregate of 145,180 shares of common stock with an exercise price of $0.01

AVITA Medical, Inc. Insider Trading and Securities Dealing Policy **

Exhibit 19.0 AVITA MEDICAL, INC. INSIDER TRADING AND SECURITIES DEALING POLICY Effective as of June 13, 2024 INTRODUCTION While performing your duties for AVITA Medical, Inc. or AVITA Medical Americas, LLC (collectively, “AVITA Medical”) you may, at times, have information that is not generally available to the public about AVITA Medical or “Related Entities” (defined below). AVITA Medical has its

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39059 AVITA MEDICAL,

Third Amendment to Orbimed Credit Agreement dated November 7, 2024**

Exhibit 10.49 THIRD AMENDMENT TO CREDIT AGREEMENT This THIRD AMENDMENT TO CREDIT AGREEMENT (this “Amendment”) is made and entered into as of November 7, 2024 by and among AVITA MEDICAL, INC., a Delaware corporation (the “Borrower”), ORCO IV LLC and ORBIMED ROYALTY & CREDIT OPPORTUNITIES IV OFFSHORE, LP, as Lenders, and ORCO IV LLC, as administrative agent for the Lenders (together with its Affilia

AVITA Medical Reports Fourth Quarter and Full Year 2024 Financial Results

Exhibit 99.1 AVITA Medical Reports Fourth Quarter and Full Year 2024 Financial Results VALENCIA, Calif., February 13, 2025 — AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today reported financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights and Recen

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2025 AVITA Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39059 85-1021707 (State or Other Jurisdiction of Incorporation) (Commission F

Subsidiaries of the Registrant **

Exhibit 21.1 List of Subsidiaries Subsidiary Name Place of % Business Purpose Incorporation Held AVITA Medical Americas, LLC Delaware 100 U.S. operations Dissolved Entities: Subsidiary Name Place of % Business Purpose Incorporation Previously Held AVITA Medical Pty Limited Australia 100 Operating company AVITA Medical Europe Limited United Kingdom 100 EMEA operations Visiomed Group Pty Ltd Austral

Second Amendment to OrbiMed Credit Agreement dated May 28, 2024 **

Exhibit 10.48 SECOND AMENDMENT TO CREDIT AGREEMENT This SECOND AMENDMENT TO CREDIT AGREEMENT (this “Amendment”) is made and entered into as of May 28, 2024 by and among AVITA MEDICAL, INC., a Delaware corporation (the “Borrower”), ORCO IV LLC and ORBIMED ROYALTY & CREDIT OPPORTUNITIES IV OFFSHORE, LP, as Lenders, and ORCO IV LLC, asadministrative agent for the Lenders (together with its Affiliates

Fourth Amendment to the Credit Agreement between the Lender and the Company, dated February 13, 2025

Exhibit 10.1 Fourth AMENDMENT TO CREDIT AGREEMENT This FOURTH AMENDMENT TO CREDIT AGREEMENT (this “Amendment”) is made and entered into as of February 13, 2025 by and among AVITA MEDICAL, INC., a Delaware corporation (the “Borrower”), ORCO IV LLC and ORBIMED ROYALTY & CREDIT OPPORTUNITIES IV OFFSHORE, LP, as Lenders, and ORCO IV LLC, as administrative agent for the Lenders (together with its Affil

First Amendment to Lease Agreement between the registrant and Hartco Ventura Inc. dated November 5, 2020 **

Exhibit 10.47 FIRST AMENDMENT TO LEASE (Units l,J,K,L,M,N,H) THIS FIRSTAMENDMENT TO LEASE made and entered into this 5TH day of November, 2020 by and betweenHartco-Ventura, Inc. as current Landlord, hereinafter referred to as "Lessor", and Avita Medical Americas, LLC, A Delaware Limited Liability Company hereinafter referred to as "Lessee". WITNESSETH WHEREAS, Lessor leased certain premises in the

AVITA Medical Updates Expected Fourth Quarter and Full Year 2024 Revenue, Provides 2025 Financial Guidance

EX-99.1 2 rcel-ex991.htm EX-99.1 Exhibit 99.1 AVITA Medical Updates Expected Fourth Quarter and Full Year 2024 Revenue, Provides 2025 Financial Guidance VALENCIA, Calif., January 7, 2025 (GLOBE NEWSWIRE) — AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced a

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 07, 2025 AVITA Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39059 85-1021707 (State or Other Jurisdiction of Incorporation) (Commission Fi

Separation Agreement and Release between the registrant and Donna Shiroma dated June 28, 2024

Exhibit 10.3 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT BOTH (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED SEPARATION AGREEMENT AND RELEASE This Separation Agreement and Release (“Agreement”) is made by and between Donna Shiroma (“Employee”) and AVITA Medical, Inc. and AVITA Medical Americas, LLC (collectively, the “Company”) (E

AVITA Medical Reports Third Quarter Financial Results

Exhibit 99.1 AVITA Medical Reports Third Quarter Financial Results VALENCIA, Calif., November 7, 2024 — AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today reported financial results for the third quarter ended September 30, 2024. Financial Results and Recent Business

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39059 AVITA MEDICAL, I

Executive Employment Agreement between the registrant and Nicole Kelsey dated June 28, 2024

Exhibit 10.2 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT BOTH (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”) is made and entered into by and between AVITA Medical, Inc. and AVITA Medical Americas, LLC. (collectively, the “Company”) and Nicole Kels

Exclusive Development and Distribution Agreement between the registrant and Collagen Matrix, Inc. dba Regenity Biosciences dated July 31, 2024

Exhibit 10.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT BOTH (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED EXCLUSIVE DEVELOPMENT AND DISTRIBUTION AGREEMENT THIS EXCLUSIVE DEVELOPMENT AND DISTRIBUTION AGREEMENT (this “Agreement”) is made and entered into effective as of the 31st day of July 2024 (the “Effective Date”), by and bet

First Amendment to Lease Agreement between the registrant and Hartco Ventura Inc. dated September 12, 2024

Exhibit 10.4 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT BOTH (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED FIRST AMENDMENT TO LEASE ( UNIT -G) THIS FIRST AMENDMENT TO LEASE made and entered into this 12rn day of September , 2024 by and betweenHartco-Ventura, Inc. as current Landlord, hereinafter referred to as "Lessor", and Avit

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 07, 2024 AVITA Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39059 85-1021707 (State or Other Jurisdiction of Incorporation) (Commission F

Filing Fee Table*

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) AVITA Medical, Inc.

AVITA Medical Reports Second Quarter Financial Results

Exhibit 99.1 AVITA Medical Reports Second Quarter Financial Results VALENCIA, Calif., August 8, 2024 — AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today reported financial results for the second quarter ended June 30, 2024. Financial Results and Recent Business Updat

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 08, 2024 AVITA Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39059 85-1021707 (State or Other Jurisdiction of Incorporation) (Commission Fil

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

As filed with the Securities and Exchange Commission on August 8, 2024 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39059 AVITA MEDICAL, INC. (

AVITA Medical Expands Portfolio with Unique Dermal Matrix to Advance Wound Care Exclusive development and distribution agreement with Regenity Biosciences provides AVITA Medical with the commercialization rights to a unique collagen-based dermal matr

Exhibit 99.1 AVITA Medical Expands Portfolio with Unique Dermal Matrix to Advance Wound Care Exclusive development and distribution agreement with Regenity Biosciences provides AVITA Medical with the commercialization rights to a unique collagen-based dermal matrix following 510(k) clearance VALENCIA, Calif., July 31, 2024 (GLOBE NEWSWIRE)— AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercia

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2024 AVITA Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39059 85-1021707 (State or Other Jurisdiction of Incorporation) (Commission File

AVITA Medical Appoints Nicole Kelsey as Chief Legal and Compliance Officer, and Corporate Secretary Donna Shiroma retires after distinguished service as General Counsel

Exhibit 99.1 AVITA Medical Appoints Nicole Kelsey as Chief Legal and Compliance Officer, and Corporate Secretary Donna Shiroma retires after distinguished service as General Counsel VALENCIA, Calif., July 1, 2024 (GLOBE NEWSWIRE) — AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin rest

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2024 AVITA Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39059 85-1021707 (State or Other Jurisdiction of Incorporation) (Commission File

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 05, 2024 AVITA Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39059 85-1021707 (State or Other Jurisdiction of Incorporation) (Commission File

AVITA Medical Announces FDA Approval of RECELL GO

Exhibit 99.1 AVITA Medical Announces FDA Approval of RECELL GO VALENCIA, Calif., May 30, 2024 (GLOBE NEWSWIRE) — AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that the U.S. Food and Drug Administration (FDA) has approved its premarket approval (PMA) sup

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2024 AVITA Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39059 85-1021707 (State or Other Jurisdiction of Incorporation) (Commission File N

Amendment of Solicitation/Modification of Contract dated February 16, 2024 by and between the registrant and

Exhibit 10.3 HHSO100201500028C P00015 Page 3 of 4 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT BOTH (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED The purpose of this modification is to add and fund CLINS 0011, 0012, & 0013. ARTICLE B.3. OPTION PRICES is hereby modified as follows: CLIN Period of Performance Supplies/ Services Unit

Exclusive Distribution Agreement between AVITA Medical Americas, LLC and Stedical Scientific, Inc, dated January 10, 2024

Exhibit 10.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT BOTH (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED EXCLUSIVE DISTRIBUTION AGREEMENT This Exclusive Distribution Agreement (this "Agreement"), is effective as of the date of the last signature (the "Effective Date"), and is entered into between AVITA Medical Americas, LLC ha

AVITA Medical Reports First Quarter Financial Results

Exhibit 99.1 AVITA Medical Reports First Quarter Financial Results VALENCIA, Calif., May 13, 2024 — AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today reported financial results for the first quarter ended March 31, 2024. Financial Results and Recent Business Updates

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39059 AVITA MEDICAL, INC.

Second Amendment to Lease Agreement between the registrant and Hartco Ventura Inc. dated January 1, 2024

Exhibit 10.2 SECOND AMENDMENT TO LEASE (Units I,J,K,L,M,N,H) THIS SECOND AMENDMENT TO LEASE made and entered into this 1st day of January, 2024 by and between Hartco-Ventura, Inc. as current Landlord, hereinafter referred to as "Lessor", and Avita Medical Americas, LLC, A Delaware Limited Liability Company hereinafter referred to as "Lessee". WITNESSETH WHEREAS, Lessor leased certain premises in t

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2024 AVITA Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39059 85-1021707 (State or Other Jurisdiction of Incorporation) (Commission File N

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to Section 240.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 10, 2024 AVITA Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39059 85-1021707 (State or Other Jurisdiction of Incorporation) (Commission File

AVITA Medical Updates Expected First Quarter 2024 Revenue

Exhibit 99.1 AVITA Medical Updates Expected First Quarter 2024 Revenue VALENCIA, Calif., April 10, 2024 (GLOBE NEWSWIRE) — AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced an update to its expected commercial revenue for the first quarter of 2024 and reaff

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to Section 240.

Amendment One to Employment Agreement between the registrant and Donna Shiroma, dated March 23, 2022** †

Exhibit 10.31 AMENDMENT ONE TO EXECUTIVE EMPLOYMENT AGREEMENT THIS AMENDMENT ONE (“Amendment One”) made and entered into on March 23, 2022, to the EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”), by and between Avita Medical Ltd, an Australian corporation (the “Company”) and Donna Shiroma, an individual (the “Executive”). The Company and Executive are sometimes referred to individually as a “Part

Patent Security Agreement

Exhibit 10.37 Execution Version PATENT SECURITY AGREEMENT This PATENT SECURITY AGREEMENT, dated as of 11 December, 2023 (this “Agreement”), is made by AVITA MEDICAL PTY LIMITED ACN 058 466 523 , an Australian proprietary company limited by shares (the “Grantor”), in favor of ORCO IV LLC, a Delaware limited liability company (together with its Affiliates, successors, transferees and assignees, the

Supplement to Pledge and Security Agreement

Exhibit 10.38 Execution Version SUPPLEMENT TO PLEDGE AND SECURITY AGREEMENT This SUPPLEMENT, dated as of 11 December, 2023 (this “Supplement”), is to the Pledge and Security Agreement, dated as of October 18, 2023 (as amended, supplemented, amended and restated or otherwise modified from time to time, the “Security Agreement”), among the Grantors (such term, and other terms used in this Supplement

Supplement to Guarantee

Exhibit 10.36 Execution Version SUPPLEMENT TO GUARANTEE This SUPPLEMENT, dated as of 11 December, 2023 (this “Supplement”), is to the Guarantee, dated as of October 18, 2023 (as amended, supplemented, amended and restated or otherwise modified from time to time, the “Guarantee”), by the Guarantors (such term, and other terms used in this Supplement, to have the meanings set forth in Article I of t

AVITA Medical Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides 2024 Financial Guidance

Exhibit 99.1 AVITA Medical Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides 2024 Financial Guidance VALENCIA, Calif., February 22, 2024 — AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today reported financial results for the fourth quarter and f

Amendment Two to Employment Agreement between the registrant and Donna Shiroma, dated August 9, 2023** †

Exhibit 10.32 AMENDMENT TWO TO EXECUTIVE EMPLOYMENT AGREEMENT THIS AMENDMENT TWO (“Amendment Two”) to the EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”), by and between Avita Medical Americas, LLC, a limited liability company incorporated in Delaware (the “Company”) and Donna Shiroma, an individual (the “Executive”). The Company and Executive are sometimes referred to individually as a “Party” a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39

Lease Agreement between the registrant and Hartco Ventura Inc. dated December 6, 2023**

Exhibit 10.30 STANDARD INDUSTRIAL/COMMERCIAL MULTI-TENANT LEASE GROSS AMERICAN INDUSTRIAL REAL ESTATE ASSOCIATION 1. Basic Provisions ("Basic Provisions"). 1.1 Parties: This Lease ("Lease"), dated for reference purposes only, December 06, 2023 is made by and between Hartco Ventura Inc.(“Lessor”) and Avita Medical Americas(“Lessee”), (collectively the "Parties," or individually a "Party"). 1.2(a) P

General Security Deed

Exhibit 10.41 Execution version General security deed AVITA  AVITA Medical Pty Limited (Grantor) ORCO IV LLC (Secured Party)  3rd Floor Randall House 6 Dowgate Hill London EC4R 2SU United Kingdom T +44 20 7429 2780 F +44 20 7429 2788 minterellison.com LON110611753 General security deed AVITA Details 5 Parties 5 Background 5 Agreed terms 6 1. Defined terms & interpretation 6 1.1. Defined terms fr

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2024 AVITA Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39059 85-1021707 (State or Other Jurisdiction of Incorporation) (Commission F

Incentive-Based Compensation Recovery Policy**†

Exhibit 97.1 AVITA MEDICAL, INC. Incentive-BASED Compensation Recovery Policy Adopted November 8, 2023 1. Policy Purpose. The purpose of this AVITA Medical, Inc. (and its subsidiaries and affiliates) (the “Company”) Incentive-Based Compensation Recovery Policy (the “Policy”) is to enable the Company to recover Erroneously Awarded Compensation in the event that the Company is required to prepare an

Waiver and First Amendment to Orbimed Credit Agreement**

Exhibit 10.34 Execution Version WAIVER AND FIRST AMENDMENT TO CREDIT AGREEMENT This WAIVER AND FIRST AMENDMENT TO CREDIT AGREEMENT (this “Amendment”) is made and entered into as of November 30, 2023 by and among AVITA MEDICAL, INC., a Delaware corporation (the “Borrower”), ORCO IV LLC, as a Lender (the “Initial Lender”), and ORCO IV LLC, as administrative agent for the Lenders (together with its A

Exclusive Distribution Agreement between the registrant and PolyMedics Innovation GmbH

Exhibit 10.42 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT BOTH (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED EXCLUSIVE DISTRIBUTION AGREEMENT This Exclusive Distribution Agreement (this "Agreement"), is effective as of the date of the last signature (the "Effective Date"), and is entered into between AVITA Medical Americas, LLC h

Trademark Security Agreement

Exhibit 10.35 Execution Version TRADEMARK SECURITY AGREEMENT This TRADEMARK SECURITY AGREEMENT, dated as of 11 December, 2023 (this “Agreement”), is made by AVITA MEDICAL PTY LIMITED ACN 058 466 523, an Australian proprietary company limited by shares (the “Grantor”), in favor of ORCO IV LLC, a Delaware limited liability company (together with its Affiliates, successors, transferees and assignees,

Specific security Deed (marketable securities)

Execution version Specific security deed (marketable securities) AVITA  AVITA Medical, Inc.

Amendment One to Employment Agreement between the registrant and David O'Toole, dated August 9, 2023** †

Exhibit 10.33 AMENDMENT ONE TO EXECUTIVE EMPLOYMENT AGREEMENT THIS AMENDMENT (“Amendment”) to the EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”), by and between AVITA Medical, Inc a Delaware corporation and its wholly owned subsidiary, AVITA Medical Americas, LLC, a Delaware limited liability company (the “Company”) and David O’Toole, an individual (the “Executive”). The Company and Executive ar

Security Trust Deed

Exhibit 10.39 Execution version Security trust deed AVITA Security Trust  ORCO IV LLC (Security Trustee) ORCO IV LLC (Administrative Agent) AVITA Medical, Inc. (Borrower) Each entity named in Schedule 1 (each an Initial Beneficiary) Each entity named in Schedule 2 (each an Initial Security Provider)  3rd Floor Randall House 6 Dowgate Hill London EC4R 2SU United Kingdom T +44 20 7429 2780 F +44 2

RCEL / AVITA Medical, Inc. / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Avita Medical Inc Title of Class of Securities: Common Stock CUSIP Number: 05380C102 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b) ☐ Rule

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2024 AVITA Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39059 85-1021707 (State or Other Jurisdiction of Incorporation) (Commission Fi

AVITA Medical Announces Preliminary 2023 Financial Highlights, Provides 2024 Financial Guidance and Business Update

Exhibit 99.1 AVITA Medical Announces Preliminary 2023 Financial Highlights, Provides 2024 Financial Guidance and Business Update VALENCIA, Calif., January 10, 2024 (GLOBE NEWSWIRE) — AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a commercial-stage regenerative medicine company focused on first-in-class devices and autologous cellular therapies for skin restoration, today announced

AVITA Medical Announces Exclusive Distribution Agreement with Stedical Scientific

Exhibit 99.2 AVITA Medical Announces Exclusive Distribution Agreement with Stedical Scientific VALENCIA, Calif., January 10, 2024 (GLOBE NEWSWIRE) — AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a commercial-stage regenerative medicine company focused on first-in-class devices and autologous cellular therapies for skin restoration, today announced it has entered into an exclusive m

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39059 AVITA MEDICAL, I

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 09, 2023 AVITA Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39059 85-1021707 (State or Other Jurisdiction of Incorporation) (Commission F

AVITA Medical Reports Third Quarter Financial Results with 51% Revenue Growth over the Same Period the Prior Year

Exhibit 99.1 AVITA Medical Reports Third Quarter Financial Results with 51% Revenue Growth over the Same Period the Prior Year VALENCIA, Calif., November 9, 2023 — AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today reported

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 20, 2023 AVITA Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39059 85-1021707 (State or Other Jurisdiction of Incorporation) (Commission Fi

Warrant Certificate, dated October 18, 2023, by and between the Company, and OrbiMed Royalty & Credit Opportunities IV, LP (incorporated by reference to Exhibit 4.1 to the registrant's Form 8-K filed on October 18, 2023)

Exhibit 4.1 Execution Version WARRANT CERTIFICATE Warrant Shares Issuable: 409,661 Common Shares Issue Date: October 18, 2023 FOR VALUE RECEIVED, AVITA MEDICAL, INC., a Delaware corporation (the “Company”), hereby certifies that ORBIMED ROYALTY & CREDIT OPPORTUNITIES IV, LP, a Delaware limited partnership (the “Initial Holder” and, together with its successors and permitted transferees and assigns

AVITA Medical, Inc. Warrant to Purchase 409,661 Shares of Common Stock

Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-271276 PROSPECTUS SUPPLEMENT (to the Prospectus dated April 25, 2023) AVITA Medical, Inc. Warrant to Purchase 409,661 Shares of Common Stock Pursuant to this prospectus supplement and the accompanying prospectus, we are offering a warrant to purchase an aggregate of 409,661 shares of common stock with an exercise price of $10.

Pledge and Security Agreement, dated October 18, 2023, by and among the Company, the guarantors party thereto and ORCO IV LLC (incorporated by reference to Exhibit 10.2 to the registrant's Form 8-K filed on October 18, 2023)

Exhibit 10.2 Execution Version PLEDGE AND SECURITY AGREEMENT This PLEDGE AND SECURITY AGREEMENT, dated as of October 18, 2023 (as amended, supplemented or otherwise modified from time to time, this “Security Agreement”), is made by AVITA MEDICAL, INC., a Delaware corporation (the “Borrower”), and the other entities listed on Annex A hereto (together with the Borrower and any other entity that may

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2023 AVITA Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39059 85-1021707 (State or Other Jurisdiction of Incorporation) (Commission Fi

AVITA Medical Announces Preliminary Third Quarter 2023 Financial Highlights and Secures up to $90 million of Non-Dilutive Debt Financing with OrbiMed to Support Growth Initiatives

Exhibit 99.1 AVITA Medical Announces Preliminary Third Quarter 2023 Financial Highlights and Secures up to $90 million of Non-Dilutive Debt Financing with OrbiMed to Support Growth Initiatives • Preliminary commercial revenue of $13.5 million for the third quarter 2023; full year 2023 guidance confirmed • $40 million funded at close; $50 million of additional non-dilutive capital available at the

Credit Agreement, dated October 18, 2023, by and between the Company, as borrower, and ORCO IV LLC as lender and administrative agent (incorporated by reference to Exhibit 10.1 to the registrant's Form 8-K filed on October 18, 2023)

Exhibit 10.1 Execution Version CREDIT AGREEMENT dated as of October 18, 2023 by and among AVITA MEDICAL, INC., as the Borrower, ORCO IV LLC, as the Initial Lender, and ORCO IV LLC, as the Administrative Agent TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND ACCOUNTING TERMS 1 SECTION 1.1 Defined Terms. 1 SECTION 1.2 Use of Defined Terms 23 SECTION 1.3 Cross-References 23 SECTION 1.4 Accounting and

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 02, 2023 AVITA Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39059 85-1021707 (State or Other Jurisdiction of Incorporation) (Commission Fi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2023 AVITA Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39059 85-1021707 (State or Other Jurisdiction of Incorporation) (Commission Fil

Executive Employment Agreement between the registrant and David O'Toole dated June 17, 2023 (incorporated by reference to Exhibit 10.3 to the registrants Form 10Q filed August 10, 2023) †*

Exhibit 10.3 EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”) is made and entered into by and between AVITA Medical, Inc. and AVITA Medical Americas, LLC. (collectively, the “Company”) and David O’Toole, an individual (the “Executive”) with reference to the following: RECITALS WHEREAS, the Company desires to employ Executive to serve as the Chief Financial Offic

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39059 AVITA MEDICAL, INC. (

AVITA Medical Reports Second Quarter Financial Results

AVITA Medical Reports Second Quarter Financial Results VALENCIA, California, August 10, 2023 — AVITA Medical, Inc.

Filing Fee Table*

EX-FILING FEES Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) AVITA Medical, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price Fee Rate Amount

As filed with the Securities and Exchange Commission on June 30, 2023

S-8 As filed with the Securities and Exchange Commission on June 30, 2023 Registration No.

June 2023 Expanded FDA Indication Update.

EX-99.1 Exhibit 99.1 Full-Thickness Skin Defects (“FTSD”) Market Sizing – June 2023 Update Market Size Additional Market Opportunity (1) (1) Prior to FDA Approval with FDA Approved Expanded Indication of FTSD Traumatic Wounds Traumatic Wounds Surgical Wounds Data • Degloving (Open Wounds) 99,000 • Gun Shot Wounds • Muscle-only Flap pending Data • Crush 2,000 • Traumatic Hematoma • Laparotomy pendi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2023 AVITA Medical, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2023 AVITA Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39059 85-1021707 (State or other jurisdiction of incorporation) (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2023 AVITA Medical, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2023 AVITA Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39059 85-1021707 (State or other jurisdiction of incorporation) Commission File N

AVITA Medical Announces Appointment of David O’Toole as Chief Financial Officer

EX-99.1 Exhibit 99.1 AVITA Medical Announces Appointment of David O’Toole as Chief Financial Officer VALENCIA, Calif., June 15, 2023 and MELBOURNE, Australia, June 16, 2023 (GLOBE NEWSWIRE) — AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, to

Amendment No. 1 to the 2020 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.1 of the Registrant’s Form 8-K filed on June 7, 2023) †

EX-10.1 Exhibit 10.1 AMENDMENT NO. 1 TO THE 2020 OMNIBUS INCENTIVE PLAN This Amendment No. 1, dated March 15, 2023 (this “Amendment”), amends the 2020 Omnibus Incentive Plan (the “Plan”), of AVITA Medical, Inc. (formerly known as AVITA Therapeutics, Inc.), a Delaware corporation (the “Company”), subject to approval of the stockholders of the Company, as set forth below. Defined terms used herein,

AVITA Medical, Inc. Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.2 of the Registrant’s Form 8-K filed on June 7, 2023) †

EX-10.2 Exhibit 10.2 AVITA MEDICAL, INC. EMPLOYEE STOCK PURCHASE PLAN 1. PURPOSE This Avita Medical, Inc. Employee Stock Purchase Plan is to encourage and to enable Eligible Employees of the Company and its Participating Subsidiaries, through payroll deductions, to acquire proprietary interests in the Company through the purchase and ownership of shares of Common Stock. The Company intends that th

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2023 AVITA Medical, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2023 AVITA Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39059 85-1021707 (State or other jurisdiction of incorporation) (Commission File N

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 AVITA Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39059 85-1021707 (State or other jurisdiction of incorporation

-FQ1 2023-

EX-99.2 Exhibit 99.2 AVITA Medical, Inc. ASX:AVH FQ1 2023 Earnings Call Transcripts Thursday, May 11, 2023 8:30 PM GMT S&P Global Market Intelligence Estimates -FQ1 2023- -FQ2 2023- -FY 2023- -FY 2024- CONSENSUS ACTUAL SURPRISE CONSENSUS CONSENSUS CONSENSUS EPS Normalized (0.37) (0.55) NM (0.52) (0.63) (0.31) Revenue (mm) 15.37 15.76 2.54 17.35 71.39 100.56 Currency: AUD Consensus as of Apr-17-202

AVITA Medical Reports First Quarter Financial Results and Affirms Full Year Guidance

EX-99.1 Exhibit 99.1 AVITA Medical Reports First Quarter Financial Results and Affirms Full Year Guidance VALENCIA, California, May 11, 2023 and MELBOURNE, Australia, May 12, 2023 — AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restorati

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 AVITA Medical, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 AVITA Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39059 85-1021707 (State or other jurisdiction of incorporation) (Commission File N

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39059 AVITA MEDICAL, INC.

Non-Qualified Deferred Compensation Plan (incorporated by reference to Exhibit 10.4 on Form 10Q issued May 11, 2023) †

Exhibit 10.4 ADOPTION AGREEMENT DEFERRED COMPENSATION PLAN The undersigned Company acting on behalf of itself and each Participating Employer, having been duly advised by its own counsel as to the legal and tax consequences of adopting this Deferred Compensation Plan, and having determined that adoption of this Plan as an unfunded, nonqualified deferred compensation plan (intending that the same c

Lease agreement between URP X LLC and AVITA Medical, Inc. dated May 11, 2023 (incorporated by reference to Exhibit 10.5 on Form 10Q issued May 11, 2023)

Exhibit 10.5 LEASE BETWEEN URP X LLC AND AVITA MEDICAL, INC. LEASE (Short Form) LEASE THIS LEASE is made as of , by and between URP X LLC, a Delaware limited liability company, hereafter called “Landlord,” and AVITA MEDICAL, INC., a California corporation, hereafter called “Tenant.” ARTICLE 1. BASIC LEASE PROVISIONS Each reference in this Lease to the “Basic Lease Provisions” shall mean and refer

Up to 3,799,164 Shares of AVITA Medical, Inc. Common Stock

424B2 Table of Contents Filed Pursuant to Rule 424(b)(2) Registration No. 333-271276 PROSPECTUS SUPPLEMENT (to the Prospectus dated April 25, 2023) Up to 3,799,164 Shares of AVITA Medical, Inc. Common Stock We have entered into a sales agreement with Cowen and Company, LLC, or Cowen, relating to shares of our common stock offered by this prospectus supplement and the accompanying prospectus. In ac

AVITA Medical to Announce First Quarter 2023 Financial Results

EX-99.1 Exhibit 99.1 AVITA Medical to Announce First Quarter 2023 Financial Results Valencia, Calif., April 20, 2023 and MELBOURNE, Australia, April 21, 2023 (GLOBE NEWSWIRE) — AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, announced today t

AVITA Medical, Inc. 28159 Stanford Avenue, Suite 220 Valencia, California 91355

CORRESP AVITA Medical, Inc. 28159 Stanford Avenue, Suite 220 Valencia, California 91355 April 21, 2023 Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Nicholas O’Leary Re: AVITA Medical, Inc. Registration Statement on Form S-3 Filed on April 14, 2023 File No. 333-271276 Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act of 1933,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 20, 2023 AVITA Medical, Inc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 20, 2023 AVITA Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39059 85-1021707 (State or other jurisdiction of incorporation) (Commission File

Filing Fee Table*

EX-FILING FEES 5 d435307dexfilingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) AVITA Medical, Inc (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregat

Power of Attorney (included in the signature page hereto)

S-3 Table of Contents As filed with the Securities and Exchange Commission on April 14, 2023 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to Section 240.

Sales Agreement, by and between the Company and Cowen and Company, LLC, dated April 14, 2023*

Exhibit 1.2 AVITA MEDICAL, INC. 3,799,164 SHARES OF COMMON STOCK SALES AGREEMENT April 14, 2023 Cowen and Company, LLC 599 Lexington Avenue, 25th Floor New York, NY 10022 Ladies and Gentlemen: AVITA Medical, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows: 1. Issuance and Sale of Shares. The Company agrees th

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

PRE 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to Section 240.

Engagement Letter dated March 22, 2023, between AVITA Medical, Inc. and Mr. Robert McNamara (incorporated by reference to Exhibit 10.1 on Form 8K issued March 27, 2023)

EX-10.1 Exhibit 10.1 March 22, 2023 Robert McNamara 56 Politzer Drive Menlo Park, CA 94025 Re: Appointment to Board of Directors Dear Mr. McNamara: I am pleased to confirm our offer regarding your appointment as a member of the Board of Directors of AVITA Medical Inc., a Delaware corporation (the “Company”), which will commence with effect on April 1, 2023 (the “Effective Date”), on the following

AVITA Medical Appoints New

EX-99.1 Exhibit 99.1 AVITA Medical Appoints New Non-Executive Member to the Board of Directors March 23, 2023 VALENCIA, Calif. and MELBOURNE, Australia, March 23, 2023 (GLOBE NEWSWIRE) — AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, announc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2023 AVITA Medical, Inc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2023 AVITA Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39059 85-1021707 (State or other jurisdiction of incorporation) (Commission File

Amendment One to Employment Agreement between the registrant and James Corbett, dated March 16, 2023 (incorporated by reference to Exhibit 10.1 of the registrant’s Form 8-K filed on March 22, 2023) †

EX-10.1 Exhibit 10.1 AMENDMENT ONE TO EMPLOYMENT AGREEMENT THIS AMENDMENT ONE (“Amendment One”) made and entered into on March 16, 2023 to the EMPLOYMENT AGREEMENT (the “Agreement”), by and between AVITA Medical Inc., a Delaware corporation (the “Company”) and James Corbett, an individual (“Executive”). The Company and Executive are sometimes referred to individually as a “Party” and collectively

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2023 AVITA Medical, Inc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2023 AVITA Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39059 85-1021707 (State or other jurisdiction of incorporation) (Commission File

AVITA Medical Appoints New

EX-99.1 Exhibit 99.1 AVITA Medical Appoints New Non-Executive Member to the Board of Directors March 16, 2023 VALENCIA, Calif. and MELBOURNE, Australia, March 16, 2023 (GLOBE NEWSWIRE) - AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, announc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2023 Avita Medical, Inc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2023 Avita Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39059 85-1021707 (State or other jurisdiction of incorporation) (Commission File

Engagement Letter dated March 15, 2023, between the registrant and Mr. Cary Vance (incorporated by reference to Exhibit 10.1 of the registrant’s Form 8-K filed on March 21, 2023) †

EX-10.1 Exhibit 10.1 March 15, 2023 Cary Vance 374 S. 730 E Lehi, UT 84043 Re: Appointment to Board of Directors Dear Mr. Vance: I am pleased to confirm our offer regarding your appointment as a member of the Board of Directors of AVITA Medical Inc., a Delaware corporation (the “Company”), which will commence with effect on April 1, 2023 (the “Effective Date”), on the following terms: 1. Position.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2023 AVITA Medical, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2023 AVITA Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39059 85-1021707 (State or other jurisdiction of incorporation) (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2023 AVITA Medical,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2023 AVITA Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39059 85-1021707 (State or other jurisdiction of incorporation) (Commission F

Who is AVITA Medical? Regenerative medicine company transforming the standard of care for skin restoration with its innovative cellular technology platform, the RECELL® System RECELL System includes autologous cell harvesting device that prepares, pr

EX-99.1 Accelerating Our Growth Profile Q4 2022 Investor Presentation Exhibit 99.1 Certain statements in this presentation and the accompanying oral commentary are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding our future

Stock Option Grant Agreement between the registrant and James Corbett, dated effective September 28, 2022 (incorporated by reference to Exhibit 10.23 of Form 10-K filed on February 23, 2023).

Exhibit 10.23 AVITA MEDICAL, INC. STOCK OPTION GRANT AGREEMENT Notice of Stock Option Grant AVITA Medical, Inc. (formerly, AVITA Therapeutics, Inc.) (the “Company”) has awarded to you (“Grantee”) an option to purchase up to the number of shares of Common Stock set forth below (this “Option” or “Grant”). This Grant must be approved by the Company’s stockholders at the next annual meeting of the Com

Fifth Amendment to the Lease Agreement between the registrant and 28159 Avenue Stanford Properties, LLC, (formerly RIF III-Avenue Stanford LLC), dated January 26, 2023, as amended) (incorporated by reference to Exhibit 10.24 to the registrant's Form 10-K filed on February 23, 2023)

Exhibit 10.24 FIFTH AMENDMENT TO LEASE 28159 Avenue Stanford Properties, LLC 10919 Vanowen Street North Hollywood, CA 91605 Date: January 26, 2023 Avita Medical Americas, LLC Attn: Mr. James Corbett, CEO 28159 Avenue Stanford, Suites 200/220 Valencia, CA 91355 Re: Amendment of Standard Multi-Tenant Office Lease - Gross dated October 3, 2016 ("Office Lease"), between RIF III - Avenue Stanford, LLC,

Form 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39059 AVITA M

Form of RSU Agreement (incorporated by reference to Exhibit 10.20 to the registrant's Form 10-K filed on February 23, 2023)†

Exhibit 10.20 AVITA MEDICAL, INC. restricted stock unit GRANT agreement Notice of Restricted Stock Unit Grant AVITA Medical, Inc. (the “Company”) has awarded to you (“Grantee”) restricted stock units (“Restricted Stock Units”) covering the number of shares of Common Stock set forth below (the “Restricted Stock Unit Grant” or “Grant”). Grantee Name: Date of Grant: Number of Restricted Stock Units:

Exhibit 4.1

Exhibit 4.1 DESCRIPTION OF COMMON STOCK OF AVITA MEDICAL, INC. REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following information is a summary of information concerning the common stock, par value $0.0001 per share (the “Common Stock”), of AVITA Medical, Inc. and does not purport to be complete. This summary is subject to the General Corporation Law of the State of

Form of Stock Option Grant (incorporated by reference to Exhibit 10.19 to the registrant's Form 10-K filed on February 23, 2023)†

Exhibit 10.19 AVITA MEDICAL, INC. STOCK OPTION GRANT AGREEMENT Notice of Stock Option Grant AVITA Medical, Inc. (the “Company”) has awarded to you (“Grantee”) an option to purchase up to the number of shares of Common Stock set forth below (this “Option” or “Grant”). Grantee Name: Date of Grant: Exercise Price per Share: Number of Shares: Type of Option: Country at Grant: Expiration Date: Vesting

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 9, 2023 AVITA Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39059 85-1021707 (State or other jurisdiction of incorporation) (Commission Fi

AVITA Medical to Announce Fourth Quarter and Full Year 2022 Financial Results and Provide 2023 Financial Guidance

Exhibit 99.1 AVITA Medical to Announce Fourth Quarter and Full Year 2022 Financial Results and Provide 2023 Financial Guidance Valencia, Calif., and MELBOURNE, Australia, February 9, 2023 (GLOBE NEWSWIRE) — AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin

RCEL / Avita Therapeutics / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Avita Medical Inc. Title of Class of Securities: Common Stock CUSIP Number: 05380C102 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ 

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 19, 2023 Avita Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39059 85-1021707 (State or other jurisdiction of incorporation) (Commission Fi

AVITA Medical Announces Management Changes and Fourth Quarter 2022 Earnings Conference Call

Exhibit 99.1 AVITA Medical Announces Management Changes and Fourth Quarter 2022 Earnings Conference Call VALENCIA, Calif., and MELBOURNE, Australia, January 19, 2023 (GLOBE NEWSWIRE) — AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (“AVITA Medical” or the “Company”), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therap

AVITA Medical Submits FDA PMA Application to Expand Indication to Vitiligo

Exhibit 99.1 AVITA Medical Submits FDA PMA Application to Expand Indication to Vitiligo VALENCIA, Calif., and MELBOURNE, Australia, December 19, 2022 (GLOBE NEWSWIRE) ? AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, announced today the submi

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2022 Avita Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39059 85-1021707 (State or other jurisdiction of incorporation) (Commission F

AVITA Medical Announces Results of 2022 Annual Meeting of Stockholders

Exhibit 99.2 AVITA Medical Announces Results of 2022 Annual Meeting of Stockholders VALENCIA, Calif. and MELBOURNE, Australia, December 12, 2022 (United States) / December 13, 2022 (Australia) (GLOBE NEWSWIRE) ? AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (Company), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular ther

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2022 Avita Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39059 85-1021707 (State or other jurisdiction of incorporation) (Commission F

Mr. Lou Panaccio, Chairman of the Board of AVITA Medical, Inc. Call To Order

Annual Meeting of Stockholders DECEMBER 12, 2022 (PST) / DECEMBER 13, 2022 (AEDT) Exhibit 99.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 AVITA Medical,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 AVITA Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39059 85-1021707 (State or other jurisdiction of incorporation) (Commission F

Authorized for release by the Chief Financial Officer of AVITA Medical, Inc.

Exhibit 99.1 AVITA Medical Reports Third Quarter 2022 Financial Results November 10, 2022 VALENCIA, Calif. and MELBOURNE, Australia, Nov. 10, 2022 (GLOBE NEWSWIRE) ? AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the ? Company?), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today repor

Executive Employment Agreement between the registrant and James Corbett dated September 26, 2022 (incorporated by reference to Exhibit 10.1 of the registrant's Form 10Q filed on November 10, 2022)

Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (this "Agreement") is made and entered into as of September 26, 2022, by and between James Corbett ("Executive") and Avita Medical, Inc., a Delaware corporation (the "Company"). WHEREAS, the Company desires to employ Executive and to enter into this Agreement embodying the terms of such employment, and Executive desires to enter into this

Amendment of Solicitation/Modification of Contract dated September 29, 2015 between the registrant and the U.S Department of Health and Human Services Biomedical Advanced Research and Development Authority (BARDA)*

Exhibit 10.3 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the registrant if publicly disclosed. Double asterisks denote omission. AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT 1. CONTRACT ID CODE PAGE OF PAGES 1 1 2. AMENDMENT/MODIFICATION NO. P00012 3. EFFECTIVE DATE See Block 16C 4. REQU

Amendment of Solicitation/Modification of Contract dated September 29, 2015 between the registrant and the U.S Department of Health and Human Services Biomedical Advanced Research and Development Authority (BARDA)*

Exhibit 10.2 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the registrant if publicly disclosed. Double asterisks denote omission.AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT1. CONTRACT ID CODEPAGE OF PAGES142. AMENDMENT/MODIFICATION NO.P000113. EFFECTIVE DATESee Block 16C4. REQUISITION/PU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39059 AVITA MEDICAL, I

AVITA Medical Announces FDA Breakthrough Device Designations for the RECELL® System

Exhibit 99.1 ASX/News Release AVITA Medical Announces FDA Breakthrough Device Designations for the RECELL? System Valencia, Calif., November 3, 2022 and MELBOURNE, Australia, November 4 2022 (GLOBE NEWSWIRE) ? AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for sk

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2022 Avita Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39059 85-1021707 (State or other jurisdiction of incorporation) (Commission Fi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to Section 240.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statement ? Definitive Additional Materials ? Soliciting Material Pursuant to Section 240.

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 26, 2022 Avita Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39059 85-1021707 (State or other jurisdiction of incorporation) (Commission

AVITA Medical Appoints Industry Leader James Corbett as Chief Executive Officer

Exhibit 99.1 AVITA Medical Appoints Industry Leader James Corbett as Chief Executive Officer September 28, 2022 VALENCIA, Calif. and MELBOURNE, Australia, Sept. 28, 2022 (GLOBE NEWSWIRE) ? AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, annou

Transforming Lives with Skin Restoration AVITA MEDICAL OVERVIEW Patented RECELL® technology, a new treatment paradigm for burn injuries Leveraging proven RECELL® platform to advance new indications in acute traumatic wounds and vitiligo, as well a pi

Investor Webinar Briefing September 20, 2022 (U.S.) / September 21, 2022 (AU) Exhibit 99.1 Certain statements in this presentation and the accompanying oral commentary are ?forward-looking statements? within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding our

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 20, 2022 AVITA Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39059 85-1021707 (State or other jurisdiction of incorporation) (Commission

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2022 Avita Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39059 85-1021707 (State or other jurisdiction of incorporation) (Commission

AVITA Medical Achieves Positive Topline Pivotal Trial Results for Treatment of Stable Vitiligo Using the RECELL® System

Exhibit 99.1 AVITA Medical Achieves Positive Topline Pivotal Trial Results for Treatment of Stable Vitiligo Using the RECELL? System ? The study achieved its primary effectiveness endpoint of super-superiority ? AVITA Medical continues to plan for submission to FDA by the end of 2022 VALENCIA, Calif. 12 SEPTEMBER 2022 and MELBOURNE, Australia, 13 SEPTEMBER 2022 ? AVITA Medical, Inc. (NASDAQ: RCEL,

RECELL® System Insurance Coverage Begins in Japan for Treatment of Acute Burns Reimbursement in Japan will be similar to that of pricing in the United States

Exhibit 99.1 RECELL? System Insurance Coverage Begins in Japan for Treatment of Acute Burns Reimbursement in Japan will be similar to that of pricing in the United States VALENCIA, Calif. and MELBOURNE, Australia, 01 September 2022 ? AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous c

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 1, 2022 Avita Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39059 85-1021707 (State or other jurisdiction of incorporation) (Commission F

RECELL® System: FDA approved for the treatment of acute thermal burns Proprietary Spray-On SkinTM offers life changing benefits Point of care technology that is safe & effective Published health economic model demonstrating hospital cost savings Deep

August 2022 Exhibit 99.1 Certain statements in this presentation and the accompanying oral commentary are ?forward-looking statements? within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding our future financial condition, technology platform, development stra

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 29, 2022 AVITA Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39059 85-1021707 (State or other jurisdiction of incorporation) (Commission Fil

AVITA Medical Reports Second Quarter 2022 Financial Results

Exhibit 99.1 AVITA Medical Reports Second Quarter 2022 Financial Results VALENCIA, California, August 11, 2022 and MELBOURNE, Australia, August 12, 2022 ? AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the ?Company?), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, today rep

AVITA Medical Announces Topline Results from Pivotal Trial in Patients with Soft-Tissue Injuries using the RECELL® System

Exhibit 99.2 AVITA Medical Announces Topline Results from Pivotal Trial in Patients with Soft-Tissue Injuries using the RECELL? System ? AVITA Medical plans to submit PMA supplement for this new indication to FDA by the end of 2022 VALENCIA, Calif. and MELBOURNE, Australia, 11 AUGUST 2022 ? AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (Company), a regenerative medicine company that is developing a

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2022 Avita Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39059 85-1021707 (State or other jurisdiction of incorporation) (Commission Fil

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39059 AVITA MEDICAL, INC. (

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 22, 2022 Avita Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39059 85-1021707 (State or other jurisdiction of incorporation) (Commission File

AVITA MEDICAL, INC. Substantial holder notice

Exhibit 99.1 ASX/News Release AVITA MEDICAL, INC. Substantial holder notice VALENCIA, Calif., USA, and MELBOURNE, Australia 22 July 2022: AVITA Medical, Inc. (NASDAQ: RCEL, ASX:AVH) (Company) advises that it is aware of changes to its substantial holders that were previously disclosed to the market. Set out below are details, to the best of the Company?s knowledge, of a person who has ceased to be

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2022 AVITA Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39059 85-1021707 (State or other jurisdiction of incorporation) (Commission File N

Authorized for release by the Chief Financial Officer of AVITA Medical, Inc.

Exhibit 99.1 AVITA Medical Reports First Quarter 2022 Financial Results May 12, 2022 VALENCIA, Calif. and MELBOURNE, Australia, May 12, 2022 (GLOBE NEWSWIRE) ? AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the ?Company?), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, toda

RECELL® System: FDA approved for the treatment of acute thermal burns Proprietary Spray-On SkinTM offers life changing benefits Point of care technology that is safe & effective Published health economic model demonstrating hospital cost savings Deep

May 2022 Exhibit 99.2 Certain statements in this presentation and the accompanying oral commentary are ?forward-looking statements? within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding our future financial condition, technology platform, development strateg

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39059 AVITA MEDICAL, INC.

RECELL® System to be Highlighted at Upcoming Music City SCALE Multidisciplinary Dermatology Meeting

Exhibit 99.1 RECELL? System to be Highlighted at Upcoming Music City SCALE Multidisciplinary Dermatology Meeting VALENCIA, Calif. and MELBOURNE, Australia, 09 MAY 2022 ? AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (Company), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs,

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2022 Avita Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39059 85-1021707 (State or other jurisdiction of incorporation) (Commission File Nu

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2022 AVITA Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39059 85-1021707 (State or other jurisdiction of incorporation) (Commission File

AVITA Medical to Announce First Quarter 2022 Financial Results

Exhibit 99.1 ASX/News Release AVITA Medical to Announce First Quarter 2022 Financial Results Valencia, Calif., and MELBOURNE, Australia, April 28, 2022 (GLOBE NEWSWIRE) ? AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced

Avita Medical, Inc. Announces Resignation of Louis Drapeau from Board of Directors

Exhibit 99.1 Avita Medical, Inc. Announces Resignation of Louis Drapeau from Board of Directors VALENCIA, Calif. 21 April 2022 and MELBOURNE, Australia, 22 April 2022 ? AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (Company), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, a

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 19, 2022 Avita Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39059 85-1021707 (State or other jurisdiction of incorporation) (Commission File

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 4, 2022 Avita Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39059 85-1021707 (State or other jurisdiction of incorporation) (Commission File

System Data to be Presented at the American Burn Association Annual Meeting

Exhibit 99.1 RECELL? System Data to be Presented at the American Burn Association Annual Meeting April 4, 2022 Data from 15 presentations will highlight the use of the platform for the treatment of pediatric and adult burn wounds VALENCIA, Calif. and MELBOURNE, Australia, April 04, 2022 (GLOBE NEWSWIRE) ? AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is develop

Investor Webinar

Exhibit 99.2 Investor Webinar VALENCIA, Calif. and MELBOURNE, Australia, 22 March 2022 ? AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, invites shareholders and prospective investors to attend its investor webinar and presentat

AVITA Medical Announces Modification of BARDA Contract to Advance Development of RECELL

Exhibit 99.1 AVITA Medical Announces Modification of BARDA Contract to Advance Development of RECELL? System in Soft Tissue Reconstruction March 21, 2022 Funds will support completion of the ongoing pivotal clinical trial VALENCIA, Calif. and MELBOURNE, Australia, March 21, 2022 (GLOBE NEWSWIRE) ? AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2022 Avita Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39059 85-1021707 (State or other jurisdiction of incorporation) (Commission File

RECELL® System Vitiligo Clinical Trial Protocol to be Presented at the Global Vitiligo Foundation Annual Scientific Symposium

Exhibit 99.3 RECELL? System Vitiligo Clinical Trial Protocol to be Presented at the Global Vitiligo Foundation Annual Scientific Symposium VALENCIA, Calif. and MELBOURNE, Australia, 23 March 2022 ? AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for mult

One Platform. Endless Possibilities. RECELL enables Vitiligo RECELL delivers healthy skin cells regeneration of healthy skin Trauma Autologous skin cells are sprayed on patient Burns / Scalds Chronic Wounds Scar Revision Healthy skin processed using

Exhibit 99.1 February 2022 NASDAQ: RCEL ASX: AVH ?Copyright 2022 AVITA Medical. All Rights Reserved. Legal Disclaimers Certain statements in this presentation and the accompanying oral commentary are ?forward-looking statements? within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, includ

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2022 Avita Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39059 85-1021707 (State or other jurisdiction of incorporation) (Commission File

Avita Medical, Inc. Signs Agreement with Premier, Inc. to Supply the RECELL® System to Hospitals and Health Systems Across the U.S. Agreement ensures timely access to the RECELL System for the approximately 4,440 U.S. hospitals and health systems in

Exhibit 99.1 Avita Medical, Inc. Signs Agreement with Premier, Inc. to Supply the RECELL? System to Hospitals and Health Systems Across the U.S. Agreement ensures timely access to the RECELL System for the approximately 4,440 U.S. hospitals and health systems in Premier?s network VALENCIA, Calif. and MELBOURNE, Australia, 02 March 2022 ? AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2022 Avita Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39059 85-1021707 (State or other jurisdiction of incorporation) (Commission File

AVITA Medical Reports Quarter Ending December 31, 2021, and Transition Period July 1, 2021, to December 31, 2021, Financial Results

Exhibit 99.1 AVITA Medical Reports Quarter Ending December 31, 2021, and Transition Period July 1, 2021, to December 31, 2021, Financial Results VALENCIA, Calif, February 28, 2022 and MELBOURNE, Australia, March 1, 2022 ? AVITA Medical, Inc. (NASDAQ: RCEL, ASX:AVH) (the ?Company?), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-ca

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2022 AVITA Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39059 85-1021707 (State or other jurisdiction of incorporation) (Commission F

RSUs – Confirmatory Deed between the registrant and Dr. Michael Perry, dated November 12, 2019. **

Exhibit 10.12 K&L GATES RSUs - Confirmatory Deed Dr Michael Perry and AVITA MEDICAL LIMITED ACN 058 466 523 RSUs - Confirmatory Deed Date: 12 November 2019 Parties: 1. Dr Michael Perry of 300 Cook St., Denver, CO, 80206, United States (Dr Perry) 2. Avita Medical Limited ACN 058 466 523 of 28159 Avenue Stanford, Suite 220, Valencia, CA 91355, United States (Company) Background: A At the Company's 2

Executive Employment Agreement between the registrant and Michael Holder, dated effective March 22, 2021.

Exhibit 10.14 EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (the "Agreement") is made and entered into by and between AVITA Medical, Inc. and AVITA Medical Americas, LLC. (collectively, the "Company") and Michael Holder, an individual (the "Executive") with reference to the following: RECITALS WHEREAS the Company desires to employ Executive to serve as the Chief Financial Offi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-KT

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-KT ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from July 1, 2021 to December 31, 2021 Commission File Number: 001

Fourth Amendment to the Lease Agreement between the registrant and RIF III-Avenue Stanford LLC, dated August 25, 2021, as amended) (incorporated by reference to Exhibit 10.30 to the registrant’s Form 10-KT filed on February 28, 2022)

Exhibit 10.30 FOURTH AMENDMENT TO LEASE THIS FOURTH AMENDMENT TO LEASE AGREEMENT (the ?Amendment?) is entered into as of the 25th day of August, 2021, by and between RIF III ? Avenue Stanford, LLC, a California limited liability company (?Landlord?) and Avita Medical Americas, LLC, a Delaware limited liability company (?Tenant?). W I T N E S S E T H: WHEREAS, Landlord and Tenant have entered into

Executive Employment Agreement between the registrant and Dr. Michael Perry, dated November 12, 2019

Exhibit 10.11 EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT ("Agreement") is made and entered into on November 12, 2019, by and between Avita Medical Ltd., an Australian corporation (the "Company"), Avita Medical Americas, LLC ("Avita America ") and Michael Perry, an individual (the " Executive") with reference to the following: RECITALS WHEREAS, the Executive has been serving

Executive Employment Agreement between the registrant and Andrew Quick, dated effective April 1, 2019.

Exhibit 10.17 EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (the ?Agreement?) is made and entered into by and between Avita Medical Americas, LLC, (the ?Company?) and Andrew Quick, an individual (the ?Executive?) with reference to the following: RECITALS WHEREAS, the Board of Directors of the Company (the ?Board?) desires to employ Executive to serve as the Chief Technology Of

RSU Agreement between the registrant and Suzanne Crowe, dated effective December 22, 2021.

Exhibit 10.28 AVITA MEDICAL, INC. restricted stock unit GRANT agreement Notice of Restricted Stock Unit Grant AVITA Medical, Inc. (formerly, AVITA Therapeutics, Inc.) (the ?Company?) has awarded to you (?Grantee?) restricted stock units (?Restricted Stock Units?) covering the number of shares of Common Stock set forth below (the ?Restricted Stock Unit Grant? or ?Grant?). Grantee Name: Suzanne Crow

RSU Agreement between the registrant and Louis Drapeau, dated effective December 22, 2021.

Exhibit 10.26 AVITA MEDICAL, INC. restricted stock unit GRANT agreement Notice of Restricted Stock Unit Grant AVITA Medical, Inc. (formerly, AVITA Therapeutics, Inc.) (the ?Company?) has awarded to you (?Grantee?) restricted stock units (?Restricted Stock Units?) covering the number of shares of Common Stock set forth below (the ?Restricted Stock Unit Grant? or ?Grant?). Grantee Name: Louis Drapea

Executive Employment Agreement between the registrant and Erin Liberto, dated effective August 28, 2017.

Exhibit 10.16 EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT ("Agreement") is made and entered into by and between Avita Medical Ltd., an Australian corporation (the "Company"), and Erin Liberto, an individual (the "Executive") with reference to the following: RECITALS WHEREAS, the Board of Directors of the Company (the "Board") desires to employ Executive to serve as the Chief

Option Confirmatory Deed between the registrant and Dr. Michael Perry, dated November 12, 2019. **

Exhibit 10.13 K&L GATES Option Confirmatory Deed DR MICHAEL PERRY and AVITA MEDICAL LIMITED ACN 058 466 523 Option Confirmatory Deed Date: 12 November 2019 Parties: 1. Dr Michael Perry of 300 Cook St., Denver, CO, 80206, United States (Dr Perry or the Participant) 2. Avita Medical Limited ACN 058 466 523 of 28159 Avenue Stanford. Suite 220, Valencia, CA 91355, United States (Company) Background: A

RSU Agreement between the registrant and Jeremy Curnock Cook, dated effective December 22, 2021.

Exhibit 10.25 AVITA MEDICAL, INC. restricted stock unit GRANT agreement Notice of Restricted Stock Unit Grant AVITA Medical, Inc. (formerly, AVITA Therapeutics, Inc.) (the ?Company?) has awarded to you (?Grantee?) restricted stock units (?Restricted Stock Units?) covering the number of shares of Common Stock set forth below (the ?Restricted Stock Unit Grant? or ?Grant?). Grantee Name: Jeremy Curno

2020 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.29 to the registrant’s Form 10-KT filed on February 28, 2022)

Exhibit 10.29 AVITA THERAPEUTICS, INC. 2020 OMNIBUS INCENTIVE PLAN 1. General. 1.1Purpose. The purposes of this Plan are to attract and retain the best available personnel for the Company and its Affiliates, to provide additional incentives to such personnel and to promote the success of the business of the Company and its Affiliates. Capitalized terms not defined in the text are defined in Sectio

Stock Option Grant Agreement between the registrant and Jeremy Curnock Cook, dated effective December 22, 2021.

EX-10.20 14 rcel-ex1020541.htm EX-10.20 Exhibit 10.20 AVITA MEDICAL, INC. STOCK OPTION GRANT AGREEMENT Notice of Stock Option Grant AVITA Medical, Inc. (formerly, AVITA Therapeutics, Inc.) (the “Company”) has awarded to you (“Grantee”) an option to purchase up to the number of shares of Common Stock set forth below (this “Option” or “Grant”). Grantee Name: Jeremy Curnock Cook Date of Grant: Decemb

RSU Agreement between the registrant and Jan Stern Reed, dated effective December 22, 2021.

Exhibit 10.24 AVITA MEDICAL, INC. restricted stock unit GRANT agreement Notice of Restricted Stock Unit Grant AVITA Medical, Inc. (formerly, AVITA Therapeutics, Inc.) (the ?Company?) has awarded to you (?Grantee?) restricted stock units (?Restricted Stock Units?) covering the number of shares of Common Stock set forth below (the ?Restricted Stock Unit Grant? or ?Grant?). Grantee Name: Jan Stern Re

RSU Agreement between the registrant and Louis Panaccio, dated effective December 22, 2021.

Exhibit 10.27 AVITA MEDICAL, INC. restricted stock unit GRANT agreement Notice of Restricted Stock Unit Grant AVITA Medical, Inc. (formerly, AVITA Therapeutics, Inc.) (the ?Company?) has awarded to you (?Grantee?) restricted stock units (?Restricted Stock Units?) covering the number of shares of Common Stock set forth below (the ?Restricted Stock Unit Grant? or ?Grant?). Grantee Name: Louis Panacc

Subsidiaries of the Registrant (incorporated by reference to Exhibit 21.1 to the registrant’s Form 10-KT filed on February 28, 2022)

Exhibit 21.1 List of Subsidiaries Subsidiary Name Place of Incorporation % Held Business Purpose AVITA Medical Pty Limited Australia 100 Operating Company AVITA Medical Americas, LLC Delaware 100 U.S. operations AVITA Medical Europe Limited United Kingdom 100 EMEA operations Visiomed Group Pty Ltd Australia 100 Asia Pacific Operations C3 Operations Pty Ltd Australia 100 Holding company Infamed Pty

Stock Option Grant Agreement between the registrant and Jan Stern Reed, dated effective December 22, 2021.

EX-10.19 13 rcel-ex1019542.htm EX-10.19 Exhibit 10.19 AVITA MEDICAL, INC. STOCK OPTION GRANT AGREEMENT Notice of Stock Option Grant AVITA Medical, Inc. (formerly, AVITA Therapeutics, Inc.) (the “Company”) has awarded to you (“Grantee”) an option to purchase up to the number of shares of Common Stock set forth below (this “Option” or “Grant”). Grantee Name: Jan Stern Reed Date of Grant: December 22

Third Amendment to the Lease Agreement between the registrant and RIF III-Avenue Stanford LLC, dated November 17, 2020, as amended) (incorporated by reference to Exhibit 10.10 to the registrant’s Form 10-KT filed on February 28, 2022)

Exhibit 10.10 THIRD AMENDMENT TO LEASE THIS THIRD AMENDMENT TO LEASE AGREEMENT (the ?Amendment?) is entered into as of the 17th day of November, 2020, by and between RIF III ? Avenue Stanford, LLC, a California limited liability company (?Landlord?) and Avita Medical Americas, LLC, a Delaware limited liability company (?Tenant?). W I T N E S S E T H: WHEREAS, Landlord and Tenant have entered into

Stock Option Grant Agreement between the registrant and Louis Panaccio, dated effective December 22, 2021.

Exhibit 10.22 AVITA MEDICAL, INC. STOCK OPTION GRANT AGREEMENT Notice of Stock Option Grant AVITA Medical, Inc. (formerly, AVITA Therapeutics, Inc.) (the ?Company?) has awarded to you (?Grantee?) an option to purchase up to the number of shares of Common Stock set forth below (this ?Option? or ?Grant?). Grantee Name: Louis Panaccio Date of Grant: December 22, 2021 Exercise Price per Share: $12.18

Executive Employment Agreement between the registrant and Kathy McGee, dated effective December 1, 2020.

Exhibit 10.15 EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (the ?Agreement?) is made and entered into by and between AVITA Medical Americas, LLC, (the ?Company?) and Kathy McGee, an individual (the ?Executive?) with reference to the following: RECITALS WHEREAS, the Company desires to employ Executive to serve as the Chief Operating Officer of the Company; WHEREAS, the Executi

Executive Employment Agreement between the registrant and Donna Shiroma, dated effective June 25, 2018 (incorporated by reference to Exhibit 10.18 to the registrant’s Form 10-KT filed on February 28, 2022)

Exhibit 10.18 EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT ("Agreement") is made and entered into by and between Avita Medical Ltd., an Australian corporation (the "Company"), and Donna Shiroma, an individual (the "Executive") with reference to the following: RECITALS WHEREAS, the Board of Directors of the Company (the "Board") desires to employ Executive to serve as the Gene

Code of Ethics **

Exhibit 14.1 CODE OF CONDUCT AVITA MEDICAL, INC. (?COMPANY?) This Code of Conduct sets out the principles and standards which the Board, management and employees of the Company are encouraged to strive towards when dealing with each other, shareholders and the broad community. 1. RESPONSIBILITY TO SHAREHOLDERS The Company aims: a) to increase shareholder value within an appropriate framework which

Certificate of Amendment of Certificate of Incorporation (incorporated by reference to Exhibit 3.2 of the registrant’s Form 10-KT filed on February 28, 2022)

Exhibit 3.2 Delaware The First State Page 1 I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF AMENDMENT OF ?AVITA THERAPEUTICS, INC.?, CHANGING ITS NAME FROM "AVITA THERAPEUTICS, INC." TO "AVITA MEDICAL, INC.", FILED IN THIS OFFICE ON THE SECOND DAY OF DECEMBER, A.D. 2020, AT 8:40 O`CLOCK A.M. 7906862

Amended and Restated Bylaws (incorporated by reference to Exhibit 3.3 of the registrant’s Form 10-KT filed on February 28, 2022)

Exhibit 3.3 AMENDED AND RESTATED BYLAWS OF AVITA MEDICAL INC. (as amended December 22, 2021) ARTICLE I Meeting of Stockholders Section 1.1. Annual Meetings. If required by applicable law, an annual meeting of stockholders shall be held for the election of directors at such date, time and place, if any, either within or without the State of Delaware, as may be designated by resolution of the board

Stock Option Grant Agreement between the registrant and Louis Drapeau, dated effective December 22, 2021.

Exhibit 10.21 AVITA MEDICAL, INC. STOCK OPTION GRANT AGREEMENT Notice of Stock Option Grant AVITA Medical, Inc. (formerly, AVITA Therapeutics, Inc.) (the ?Company?) has awarded to you (?Grantee?) an option to purchase up to the number of shares of Common Stock set forth below (this ?Option? or ?Grant?). Grantee Name: Louis Drapeau Date of Grant: December 22, 2021 Exercise Price per Share: $12.18 N

Stock Option Grant Agreement between the registrant and Suzanne Crowe, dated effective December 22, 2021.

Exhibit 10.23 AVITA MEDICAL, INC. STOCK OPTION GRANT AGREEMENT Notice of Stock Option Grant AVITA Medical, Inc. (formerly, AVITA Therapeutics, Inc.) (the ?Company?) has awarded to you (?Grantee?) an option to purchase up to the number of shares of Common Stock set forth below (this ?Option? or ?Grant?). Grantee Name: Suzanne Crowe Date of Grant: December 22, 2021 Exercise Price per Share: $12.18 N

The RECELL® System Receives PMDA Approval in Japan and AVITA Medical will Commercialize in Partnership with COSMOTEC, an M3 Group Company

EX-99.1 2 d323781dex991.htm EX-99.1 Exhibit 99.1 The RECELL® System Receives PMDA Approval in Japan and AVITA Medical will Commercialize in Partnership with COSMOTEC, an M3 Group Company VALENCIA, Calif. and MELBOURNE, Australia, 23 February 2022 — AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2022 Avita Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39059 85-1021707 (State or other jurisdiction of incorporation) (Commission F

AVITA Medical Announces FDA Approval of New RECELL® System with Improved Ease of Use System enhanced in response to clinician workflow and usability feedback; new system simplifies process United States product launch planned for Q2 2022

Exhibit 99.1 AVITA Medical Announces FDA Approval of New RECELL? System with Improved Ease of Use System enhanced in response to clinician workflow and usability feedback; new system simplifies process United States product launch planned for Q2 2022 VALENCIA, Calif. and MELBOURNE, Australia, 17 February 2022 ? AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is d

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2022 Avita Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39059 85-1021707 (State or other jurisdiction of incorporation) (Commission F

RCEL / Avita Therapeutics / Redmile Group, LLC - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Avita Medical, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 05380C102 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant

Joint Filing Agreement

EX-99.1 2 tm226094d22ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, $0.0001

RCEL / Avita Therapeutics / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Avita Medical Inc. Title of Class of Securities: Common Stock CUSIP Number: 05380C102 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ??

AVITA Medical to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

EX-99.1 2 d307855dex991.htm EX-99.1 Exhibit 99.1 AVITA Medical to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference February 2, 2022 VALENCIA, Calif. and MELBOURNE, Australia, Feb. 02, 2022 (GLOBE NEWSWIRE) — AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables p

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 02, 2022 Avita Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39059 85-1021707 (State or other jurisdiction of incorporation) (Commission F

AVITA Medical Announces Preliminary Unaudited Results for the Quarter ended December 31, 2021

EX-99.1 2 d284283dex991.htm EX-99.1 Exhibit 99.1 AVITA Medical Announces Preliminary Unaudited Results for the Quarter ended December 31, 2021 VALENCIA, Calif, January 10, 2022 and MELBOURNE, Australia, January 11, 2022 — AVITA Medical, Inc. (NASDAQ: RCEL, ASX:AVH) (the “Company”), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-ca

Vitiligo Pivotal Trial: Enrollment Completed Soft Tissue Pivotal Trial: Enrollment Completed Transitional Pass-Through Payment Application Approved by CMS for Reimbursement in Outpatients EB: Initial Proof of Concept for Delivery of Genetically Modif

EX-99.2 3 d284283dex992.htm EX-99.2 January 2022 Exhibit 99.2 Certain statements in this presentation and the accompanying oral commentary are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding our future financial condition,

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2022 Avita Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39059 85-1021707 (State or other jurisdiction of incorporation) (Commission Fi

AVITA Medical, Inc.: Results of 2021 Annual Meeting of Shareholders

EX-99.1 3 d257419dex991.htm EX-99.1 Exhibit 99.1 AVITA Medical, Inc.: Results of 2021 Annual Meeting of Shareholders December 22, 2021 (United States) / December 23, 2021 (Australia) VALENCIA, Calif. and MELBOURNE, Australia, December 22, 2021 (United States) / December 23, 2021 (Australia) (GLOBE NEWSWIRE) — AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (Company), a regenerative medicine company t

Avita Medical, Inc. Amended and Restated Bylaws, effective December 22, 2021.

EX-3.2 2 d257419dex32.htm EX-3.2 Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF AVITA MEDICAL INC. (as amended December 22, 2021) ARTICLE I Meeting of Stockholders Section 1.1. Annual Meetings. If required by applicable law, an annual meeting of stockholders shall be held for the election of directors at such date, time and place, if any, either within or without the State of Delaware, as may be desig

Mr. Lou Panaccio, Chairman of the Board of Avita Medical, Inc. Call To Order

Annual Meeting of Stockholders DECEMBER 22, 2021 (PST) / DECEMBER 23, 2021 (AEDT) Exhibit 99.

Regulation FD Disclosure, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2021 Avita Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39059 85-1021707 (State or other jurisdiction of incorporation) (Commission F

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2021 Avita Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39059 85-1021707 (State or other jurisdiction of incorporation) (Commission F

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2021 Avita Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39059 85-1021707 (State or other jurisdiction of incorporation) (Commission F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2021 Avita Medical,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2021 Avita Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39059 85-1021707 (State or other jurisdiction of incorporation) (Commission F